Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as well [Yahoo! Finance]
Unicycive Therapeutics, Inc. (UNCY)
Company Research
Source: Yahoo! Finance
41% of the business is held by the top 25 shareholders Institutions own 12% of Unicycive Therapeutics Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To get a sense of who is truly in control of Unicycive Therapeutics, Inc. ( NASDAQ:UNCY ), it is important to understand the ownership structure of the business. With 48% stake, retail investors possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). While retail investors were the group that reaped the most benefits after last week's 23% price gain, institutions also received a 12% cut. Let's delve deeper into each type of owner of Unicycive Therapeutics, beginning with the chart below. See our latest analysis for Unicycive Therapeutics NasdaqCM:UNCY Ownership Breakdown November 18th 2025 What Does The Institutional Ownership Tell Us About Unicycive Thera
Show less
Read more
Impact Snapshot
Event Time:
UNCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UNCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UNCY alerts
High impacting Unicycive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
UNCY
News
- Unicycive Therapeutics (NASDAQ:UNCY) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Unicycive Therapeutics to Participate in Upcoming Investor Events in December [Yahoo! Finance]Yahoo! Finance
- Unicycive Therapeutics to Participate in Upcoming Investor Events in DecemberGlobeNewswire
- Unicycive Therapeutics GAAP EPS of -$0.46 beats by $0.07 [Seeking Alpha]Seeking Alpha
- Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
UNCY
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form 8-K
- 11/14/25 - Form 424B5
- UNCY's page on the SEC website